PL2744797T3 - Inhibitory dyrk1 i ich zastosowanie - Google Patents
Inhibitory dyrk1 i ich zastosowanieInfo
- Publication number
- PL2744797T3 PL2744797T3 PL12748470T PL12748470T PL2744797T3 PL 2744797 T3 PL2744797 T3 PL 2744797T3 PL 12748470 T PL12748470 T PL 12748470T PL 12748470 T PL12748470 T PL 12748470T PL 2744797 T3 PL2744797 T3 PL 2744797T3
- Authority
- PL
- Poland
- Prior art keywords
- dyrk1
- inhibitors
- dyrk1 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11178190 | 2011-08-19 | ||
| PCT/EP2012/066151 WO2013026806A1 (en) | 2011-08-19 | 2012-08-17 | Dyrk1 inhibitors and uses thereof |
| EP12748470.7A EP2744797B1 (en) | 2011-08-19 | 2012-08-17 | Dyrk1 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2744797T3 true PL2744797T3 (pl) | 2016-01-29 |
Family
ID=46704656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12748470T PL2744797T3 (pl) | 2011-08-19 | 2012-08-17 | Inhibitory dyrk1 i ich zastosowanie |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9446044B2 (pl) |
| EP (1) | EP2744797B1 (pl) |
| JP (1) | JP6017559B2 (pl) |
| KR (1) | KR102006749B1 (pl) |
| CN (1) | CN103797002B (pl) |
| AU (1) | AU2012298510B2 (pl) |
| BR (1) | BR112014003774B1 (pl) |
| CA (1) | CA2848896C (pl) |
| DK (1) | DK2744797T3 (pl) |
| EA (1) | EA026377B1 (pl) |
| ES (1) | ES2551268T3 (pl) |
| IL (1) | IL230917A (pl) |
| PL (1) | PL2744797T3 (pl) |
| PT (1) | PT2744797E (pl) |
| WO (1) | WO2013026806A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3374198B2 (ja) | 1993-02-23 | 2003-02-04 | 株式会社バルダン | 縫製方法 |
| JP3374197B2 (ja) | 1993-02-24 | 2003-02-04 | 株式会社バルダン | 縫製方法 |
| US20150292032A1 (en) * | 2012-10-10 | 2015-10-15 | Felicitex Therapeutics, Inc. | Treatment of cancer by targeting quiescent cancer cells |
| FR3002044A1 (fr) * | 2013-02-08 | 2014-08-15 | Centre Nat Rech Scient | Marqueur dyrk1a pour la maladie d'alzheimer |
| CA2854542A1 (en) | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| JP2015107945A (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| JP2018526452A (ja) * | 2015-09-03 | 2018-09-13 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Ｄｙｒｋ１ａの小分子抑制剤およびその使用 |
| CN109562176A (zh) * | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
| BR112018071023A2 (pt) * | 2016-04-15 | 2019-02-05 | Felicitex Therapeutics Inc | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose |
| WO2018119039A1 (en) | 2016-12-23 | 2018-06-28 | Felicitex Therapeutics, Inc. | Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN111819193A (zh) | 2018-01-05 | 2020-10-23 | 西奈山伊坎医学院 | 增加胰腺β细胞增殖的方法、治疗方法以及组合物 |
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US12054483B2 (en) | 2018-09-28 | 2024-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| WO2021153665A1 (ja) * | 2020-01-30 | 2021-08-05 | カルナバイオサイエンス株式会社 | 新規アルキン誘導体 |
| US20230365589A1 (en) * | 2020-09-18 | 2023-11-16 | Sumitomo Pharma Co., Ltd. | Novel amine derivatives |
| WO2022059778A1 (ja) * | 2020-09-18 | 2022-03-24 | カルナバイオサイエンス株式会社 | 環状ウレア誘導体 |
| JPWO2023008470A1 (pl) * | 2021-07-28 | 2023-02-02 | ||
| JPWO2023008472A1 (pl) * | 2021-07-28 | 2023-02-02 | ||
| WO2023140846A1 (en) * | 2022-01-20 | 2023-07-27 | Felicitex Therapeutics, Inc. | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway |
| WO2024249488A2 (en) * | 2023-05-30 | 2024-12-05 | Beth Israel Deaconess Medical Center, Inc. | Inhibitors of dyrk1a |
| AU2024352423A1 (en) | 2023-09-28 | 2026-05-14 | Graviton Pharmaceuticals B.V. | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| GB0705566D0 (en) | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
| FR2943057B1 (fr) * | 2009-03-12 | 2011-06-03 | Centre Nat Rech Scient | DERIVES DE 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO°2,1-a!ISOINDOL-6(10bH)- ONES, LEUR PROCEDE DE PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES |
| WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
-
2012
- 2012-08-17 PL PL12748470T patent/PL2744797T3/pl unknown
- 2012-08-17 BR BR112014003774-4A patent/BR112014003774B1/pt active IP Right Grant
- 2012-08-17 CA CA2848896A patent/CA2848896C/en active Active
- 2012-08-17 AU AU2012298510A patent/AU2012298510B2/en active Active
- 2012-08-17 WO PCT/EP2012/066151 patent/WO2013026806A1/en not_active Ceased
- 2012-08-17 JP JP2014525468A patent/JP6017559B2/ja active Active
- 2012-08-17 PT PT127484707T patent/PT2744797E/pt unknown
- 2012-08-17 EA EA201400245A patent/EA026377B1/ru not_active IP Right Cessation
- 2012-08-17 CN CN201280040405.7A patent/CN103797002B/zh active Active
- 2012-08-17 US US14/238,925 patent/US9446044B2/en active Active
- 2012-08-17 KR KR1020147007325A patent/KR102006749B1/ko active Active
- 2012-08-17 ES ES12748470.7T patent/ES2551268T3/es active Active
- 2012-08-17 EP EP12748470.7A patent/EP2744797B1/en active Active
- 2012-08-17 DK DK12748470.7T patent/DK2744797T3/en active
-
2014
- 2014-02-11 IL IL230917A patent/IL230917A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2848896C (en) | 2019-10-29 |
| BR112014003774B1 (pt) | 2021-12-14 |
| EP2744797B1 (en) | 2015-09-09 |
| AU2012298510A1 (en) | 2014-04-10 |
| AU2012298510B2 (en) | 2016-10-27 |
| EA201400245A1 (ru) | 2014-07-30 |
| KR20140057614A (ko) | 2014-05-13 |
| CN103797002B (zh) | 2017-02-22 |
| JP6017559B2 (ja) | 2016-11-02 |
| US9446044B2 (en) | 2016-09-20 |
| KR102006749B1 (ko) | 2019-08-02 |
| CN103797002A (zh) | 2014-05-14 |
| IL230917A0 (en) | 2014-03-31 |
| PT2744797E (pt) | 2015-11-16 |
| EP2744797A1 (en) | 2014-06-25 |
| DK2744797T3 (en) | 2015-10-19 |
| US20140275064A1 (en) | 2014-09-18 |
| CA2848896A1 (en) | 2013-02-28 |
| BR112014003774A2 (pt) | 2017-03-07 |
| HK1198827A1 (en) | 2015-06-12 |
| ES2551268T3 (es) | 2015-11-17 |
| IL230917A (en) | 2017-02-28 |
| JP2014525928A (ja) | 2014-10-02 |
| WO2013026806A1 (en) | 2013-02-28 |
| EA026377B1 (ru) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201704173B (en) | Acc inhibitors and uses thereof | |
| IL230917A (en) | 1dyrk inhibitors and their uses | |
| EP2663312A4 (en) | IRAQ INHIBITORS AND THEIR USE | |
| EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
| IL233051B (en) | Anti-phf-tau antibodies and uses thereof | |
| IL230511A0 (en) | 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors | |
| EP2696682A4 (en) | MIF-HEMMER AND USES THEREOF | |
| PL2935222T3 (pl) | Inhibitory PRMT5 i ich zastosowania | |
| IL229844B (en) | Anti-psgl-1 antibodies and their use | |
| GB201110783D0 (en) | Methods and uses | |
| GB201116774D0 (en) | Uses and methods | |
| GB201111775D0 (en) | Compounds and uses thereof | |
| GB201108490D0 (en) | Methods and uses | |
| GB201120474D0 (en) | Inhibitors | |
| ME03310B (me) | 4-IMIDAZOPIRIDAZIN-1-jL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDl КАО INHIBITORI втк | |
| GB201121726D0 (en) | Compounds and uses thereof | |
| GB201121551D0 (en) | Compounds and uses thereof | |
| GB201018597D0 (en) | Inhibitors | |
| GB201109358D0 (en) | Products and uses |